Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.


Anionic fluoroquinolone (FQ).

Current development phase: Pre-Registration

Delafloxacin is an anionic fluoroquinolone (FQ), with a good safety profile, active against both Gram positive and negative bacteria, including Methicillin-resistant Staph. aurues (MRSA) and FQs resistant strains.
Its balanced and potent activity against both DNA gyrase and topoisomerase IV could help to reduce the selection of resistant strains.
Both IV and oral formulations are available, enabling an early hospital discharge.
Delafloxacin would be an option for patients with comorbidities, more at risk to be infected with difficult-to-treat pathogens, like MRSA and multi resistant Gram negative strains, leading to recurrent infections, poor patient outcomes and higher use of healthcare resources.
On March 2017 the Menarini Group and Melinta entered into a co-development and commercial agreement in 68 Countries for Delafloxacin. Menarini will be responsible for the regulatory activities, including launch and commercialization of Delafloxacin, in the countries covered by the agreement.
A marketing authorization application for the initial indication of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) is expected to be submitted to EMA in the first quarter (Q1) of 2018.
A phase IIIb clinical trial in ABSSSI would start in Q3 2018.  A global phase 3 clinical trial in patients with Community Acquired Bacterial Pneumonia (CABP) is ongoing.

Aree terapeutiche


Discover all of Menarini's products marketed in Italy.




Advanced Technology


Il gruppo Menarini


Discover the leading Italian pharmaceutical company in the world.


La qualità al primo posto


Quality: point of departure and arrival for our drugs.